Compare CIVB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | AURA |
|---|---|---|
| Founded | 1884 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 396.8M |
| IPO Year | N/A | 2021 |
| Metric | CIVB | AURA |
|---|---|---|
| Price | $22.29 | $5.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $25.40 | $20.20 |
| AVG Volume (30 Days) | 126.4K | ★ 184.4K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 33.31 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $163,095,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $11.12 | N/A |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | ★ 11.28 | N/A |
| 52 Week Low | $17.47 | $4.35 |
| 52 Week High | $25.59 | $8.60 |
| Indicator | CIVB | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 30.64 |
| Support Level | $21.80 | $5.30 |
| Resistance Level | $22.60 | $5.58 |
| Average True Range (ATR) | 0.57 | 0.36 |
| MACD | -0.24 | -0.11 |
| Stochastic Oscillator | 18.49 | 9.71 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.